A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder
A Phase 1b, Open-label, Multiple-dose, Randomized, Parallel-arm, Safety, Tolerability, and Pharmacokinetic Trial of Aripiprazole Intramuscular Depot Administered in the Gluteal Muscle in Adult Subjects With Schizophrenia or Bipolar I Disorder
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
This PHASE1/PHASE2 trial investigates Bipolar I Disorder and Schizophrenia and is currently completed. Otsuka Pharmaceutical Development & Commercialization, Inc. leads this study, which shows 14 recorded versions since 2019 — indicating substantial longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Apr 2022 — Dec 2023 [monthly]
Completed PHASE1_PHASE2
▶ Show 9 earlier versions
-
Sep 2021 — Apr 2022 [monthly]
Completed PHASE1_PHASE2
Phase: PHASE1 → PHASE1_PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE1
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE1
-
Sep 2020 — Oct 2020 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
May 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE1
-
Jan 2020 — May 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Oct 2019 — Jan 2020 [monthly]
Recruiting PHASE1
-
Sep 2019 — Oct 2019 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Aug 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Otsuka Pharmaceutical Development & Commercialization, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .